Candriam SCA’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Candriam SCA’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-202,674	Closed	-$328K	–	849
2023 Q1	$328K	Buy	+202,674	New	+$578K	﹤0.01%	847
2020 Q4	–	Sell	-370,000	Closed	-$3.5M	–	844
2020 Q3	$3.5M	Hold	370,000	–	–	0.03%	410
2020 Q2	$3.31M	Sell	370,000 -150,000	-29%	-$1.39M	0.04%	407
2020 Q1	$4.25M	Hold	520,000	–	–	0.05%	392
2019 Q4	$4.35M	Sell	520,000 -95,000	-15%	-$874K	0.05%	404
2019 Q3	$5.57M	Buy	615,000 +200,000	+48%	+$2.24M	0.07%	294
2019 Q2	$4.45M	Buy	+415,000	New	+$4.41M	0.06%	358
2017 Q3	–	Sell	-160,000	Closed	-$1.41M	–	740
2017 Q2	$1.41M	Sell	160,000 -110,000	-41%	-$706K	0.03%	525
2017 Q1	$1.4M	Buy	270,000 +70,000	+35%	+$281K	0.03%	507
2016 Q4	$610K	Hold	200,000	–	–	0.01%	590
2016 Q3	$926K	Hold	200,000	–	–	0.02%	511
2016 Q2	$1.16M	Hold	200,000	–	–	0.03%	411
2016 Q1	$1.2M	Buy	+200,000	New	+$1.2M	0.03%	403
2015 Q1	–	Sell	-120,000	Closed	-$1.82M	–	658
2014 Q4	$1.82M	Buy	+120,000	New	+$1.46M	0.04%	367

Other funds holding SGMO

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCMU

Rokos Capital Management (UK) London, United Kingdom $13.2B AUM 85.71% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Candriam SCA's SGMO Position: Q2 2023 in Review

Candriam SCA sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2023, closing a stake of 202,674 shares — an estimated $328K sold.

Candriam SCA first reported a position in SGMO in Q4 2014 and held it in 14 quarters. The position peaked at $5.57M in Q3 2019. 152 funds tracked by Wall St. Rank hold SGMO as of Q2 2023.

Candriam SCA reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2023 after selling out during the quarter.
Candriam SCA sold 202,674 SANGAMO THERAPEUTICS INC shares in Q2 2023, an estimated $328K.
Candriam SCA first reported a position in SANGAMO THERAPEUTICS INC in Q4 2014 and held it in 14 quarters.
Candriam SCA's SANGAMO THERAPEUTICS INC position peaked at $5.57M in Q3 2019.
152 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2023.

Based on Candriam SCA's 13F filing for Q2 2023, filed 8 Aug 2023.